A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis.
Gavin GiovannoniVolker KnappertzJoshua R SteinermanAaron P TansyThomas LiStephen KriegerAntonio UccelliBernard M J UitdehaagXavier MontalbanHans-Peter HartungMaria Pia SormaniBruce A C CreeFred LublinFrederik BarkhofPublished in: Neurology (2020)
This study provides Class I evidence that, although well tolerated, laquinimod 0.6 mg did not demonstrate a significant treatment effect on PBVC in patients with PPMS.